Stenabolic comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-29. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
== Clinical importance == S. haemolyticus is the second-most clinically isolated CoNS (S. epidermidis is the first) and it is considered an important nosocomial pathogen. Human infections include: native valve endocarditis, sepsis, peritonitis, and urinary tract, wound, bone, and joint infections. Infrequent soft-tissue infections usually occur in immunocompromised patients. Like other CoNS, S. haemolyticus is often associated with the insertion of foreign bodies, such as prosthetic valves, cerebrospinal fluid shunts, orthopedic prostheses, and intravascular, urinary, and dialysis catheters. S. haemolyticus is multi-drug resistant and able to form biofilms, which makes infections especially difficult to treat.
=== First complete nucleotide sequence of a biological nucleic acid molecule === Although determining the sequence of proteins was becoming somewhat routine, methods for sequencing of nucleic acids were not available until the mid-1960s. In this seminal work, a specific tRNA was purified in substantial quantities, and then sliced into overlapping fragments using a variety of ribonucleases. Analysis of the detailed nucleotide composition of each fragment provided the information necessary to deduce the sequence of the tRNA. Today, the sequence analysis of much larger nucleic acid molecules is highly automated and much faster.
=== Combos === Combos offered by Raising Cane's feature their chicken fingers and signature dipping sauce. Depending on the combo, they will also come with other sides such as crinkle-cut fries, coleslaw, and Texas toast.
Sources: en.wikipedia.org
Hong Kong has a highly developed and sophisticated transport network. Over 90% of daily trips made by its residents are made with public transport, the highest percentage in the world. The Octopus card, a contactless smart payment card made for Hong Kong, is widely accepted on railways, trams, buses and ferries, and can also be used for payment in most retail stores. Alternative payments such as Apple Pay, AliPay, Mastercard, and Visa have also been gradually introduced as methods of payment for public transport.
On 3 September 2021, the Supreme Court of Justice ruled that the president can serve two consecutive terms in office. The ruling overturned a 2014 ruling that presidents had to wait ten years to be eligible to run for re-election. Constitutional lawyers criticized the ruling, saying that consecutive re-election violates El Salvador's constitution. The 2021 ruling allowed Bukele to run for re-election in the 2024 presidential election. ARENA and the FMLN protested the court's ruling, with an ARENA spokesperson calling it a "precursor to a dictatorship" and an FMLN representative saying that the state is serving only one person: Bukele. The ruling was also condemned by the United States government. Jean Elizabeth Manes, chargé d'affaires of the United States to El Salvador, called it "clearly contrary to the Salvadoran constitution". According to Manes, the ruling was a direct result of the May 2021 legislative replacement of the Supreme Court justices.
The entire Half-Life for PlayStation 2 package achieved gold status on October 30, 2001, and the game was released on November 14, 2001, in North America, and in Europe on November 30. In October 2005, work was begun by a group of Ukrainian developers to port Decay over to Windows, as a modification for both the old World Opponent Network and current Steam versions of Half-Life. The port relied on the discovery of a method that allowed Decay's PS2 game files to be converted to Windows version of the game. The port went into the beta development stage in December 2007 and was released publicly on September 23, 2008. The port was received well by the journalists in the industry; GameSpy site Planet Half-Life noted that it was a shame that an official PC version of Decay never emerged, while British journalist Alec Meer stated that it was "fantastic to have this short but sweet lost Half-Life episode on PC at last, and it even has something the PS2 version didn't—online play".
Sources: en.wikipedia.org
The original source of most nutrients, including micronutrients, is the geological reservoir, also called the slow pool. Micronutrients trapped in rocks and minerals must first be broken down through physical or chemical weathering before they can enter the fast pool, meaning they cycle between reservoirs on shorter timescales. Micronutrients can physically exchange between reservoirs in various ways such as from terrestrial soils to oceans via aeolian transport or fluvial transport, from oceans to marine sediments via deposition of organic matter, and from sediments to the geologic reservoir via lithification. Alternatively, micronutrients can exit the geologic reservoir through tectonic processes such as through volcanism or hydrothermal vents.
== Functions == Individual SHLPs demonstrated different biological effects. SHLP2 and SHLP3 enhanced cell viability and inhibited apoptosis in both NIT-1 and 22Rv1 cells. SHLP2 and SHLP4 promoted cell proliferation in NIT-1 β-cells. SHLP6 significantly increased apoptosis in both NIT-1 and 22Rv1 cells, having an effect opposite of SHLP2 and SHLP3. Moreover, SHLP2 and SHLP3 also induced oxygen consumption rate (OCR) and increased cellular ATP levels, which indicates that SHLP2 and 3 are mitochondrial modulators. Analysis of SHLP and humanin homologs across all vertebrates show that humanin and SHLP6 are well-conserved and subject to natural selection, suggesting that they have a biological function. SHLP4 is conserved but does not appear to be under selection.
== Therapeutic uses == Inhibition of the norepinephrine transporter (NET) has potential therapeutic applications in the treatment of attention deficit hyperactivity disorder (ADHD), substance abuse, neurodegenerative disorders (e.g., Alzheimer's disease (AD) and Parkinson's disease (PD)) and clinical depression.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.